• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌术前和术后血清CA 125水平的预后价值:新观点与多因素分析

Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.

作者信息

Makar A P, Kristensen G B, Kaern J, Børmer O P, Abeler V M, Tropé C G

机构信息

Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo.

出版信息

Obstet Gynecol. 1992 Jun;79(6):1002-10.

PMID:1579296
Abstract

The prognostic significance of the serum CA 125 level was studied in 687 patients with invasive epithelial ovarian malignancies. The samples were collected preoperatively in 200 and postoperatively in 487 patients. Median follow-up was 27 months (range 3-84). The serum CA 125 level was elevated preoperatively in 90% of cases, with a median value of 429 U/mL. In patients with evidence of disease at the time of sampling, the CA 125 serum level correlated directly to tumor stage, tumor load, and histologic grade. Using Cox multivariate analysis, the preoperative serum CA 125 level had no independent prognostic significance, whereas the postoperative level did. In patients without residual disease after primary surgery, histologic type (P less than .0001), postoperative CA 125 level with 35 U/mL as the cutoff value (P = .0009), and tumor grade (P = .034) were independent prognostic factors for survival. For those with residual tumor after primary surgery, histologic type (P less than .0001), postoperative treatment (P = .0002), size of residual disease (P = .0005), and postoperative serum CA 125 level with 65 U/mL as a cutoff (P = .003) were independent prognostic factors.

摘要

对687例浸润性上皮性卵巢恶性肿瘤患者的血清CA 125水平的预后意义进行了研究。200例患者在术前采集样本,487例患者在术后采集样本。中位随访时间为27个月(范围3 - 84个月)。90%的病例术前血清CA 125水平升高,中位值为429 U/mL。在采样时存在疾病证据的患者中,CA 125血清水平与肿瘤分期、肿瘤负荷和组织学分级直接相关。使用Cox多变量分析,术前血清CA 125水平无独立预后意义,而术后水平有。在初次手术后无残留疾病的患者中,组织学类型(P <.0001)、以35 U/mL为临界值的术后CA 125水平(P =.0009)和肿瘤分级(P =.034)是生存的独立预后因素。对于初次手术后有残留肿瘤的患者,组织学类型(P <.0001)、术后治疗(P =.0002)、残留疾病大小(P =.0005)以及以65 U/mL为临界值的术后血清CA 125水平(P =.003)是独立预后因素。

相似文献

1
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.卵巢癌术前和术后血清CA 125水平的预后价值:新观点与多因素分析
Obstet Gynecol. 1992 Jun;79(6):1002-10.
2
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?复发时的血清CA 125是否为卵巢癌患者进一步生存预后的预后指标?
Gynecol Oncol. 1993 Apr;49(1):3-7. doi: 10.1006/gyno.1993.1076.
3
Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.CA125 在卵巢上皮性癌患者囊液中的预后价值。
Oncol Rep. 2010 Feb;23(2):579-84.
4
Prognostic value of Ca 125 levels during primary therapy.原发性治疗期间Ca 125水平的预后价值。
Anticancer Res. 2007 Jul-Aug;27(4A):1837-9.
5
Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.对于晚期上皮性卵巢癌患者,6周期初始辅助化疗后的血清CA-125水平是完全缓解者生存的一个有用的预后因素。
Onkologie. 2008 Jun;31(6):315-20. doi: 10.1159/000131270. Epub 2008 May 27.
6
[Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].[上皮性卵巢癌患者术前血清血管内皮生长因子水平与CA125水平的相关性及其预后价值]
Zhonghua Fu Chan Ke Za Zhi. 2008 Jan;43(1):9-12.
7
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.结直肠癌中癌胚抗原(CEA)和糖类抗原19-9(CA 19-9)血清水平预后价值的多变量分析
Anticancer Res. 2000 Nov-Dec;20(6D):5195-8.
8
Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.术前CA-125在国际妇产科联盟I期上皮性卵巢癌中的预后重要性:一项澳大利亚多中心研究。
J Clin Oncol. 2005 Sep 1;23(25):5938-42. doi: 10.1200/JCO.2005.08.151. Epub 2005 Aug 8.
9
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.手术细胞减灭术对IV期上皮性卵巢癌生存的影响。
Gynecol Oncol. 1999 Mar;72(3):278-87. doi: 10.1006/gyno.1998.5145.
10
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平在Ⅲ期卵巢癌患者中的预后价值。
Anticancer Res. 2004 May-Jun;24(3b):1981-5.

引用本文的文献

1
Are preoperative serum cancer antigen 125 levels a prognostic factor for outcome in epithelial ovarian cancer? A systematic review.术前血清癌抗原125水平是上皮性卵巢癌预后的一个因素吗?一项系统评价。
Niger Med J. 2024 May 23;65(2):108-118. doi: 10.60787/nmj-v65i2-418. eCollection 2024 Mar-Apr.
2
Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.新型转录因子相关预后标志物预测浆液性卵巢癌。
Sci Rep. 2021 Mar 30;11(1):7207. doi: 10.1038/s41598-021-86294-z.
3
Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
血清 CA-125 水平在正常范围内升高与卵巢癌的复发风险和生存密切相关。
J Ovarian Res. 2020 Sep 2;13(1):102. doi: 10.1186/s13048-020-00681-0.
4
Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database.基于 SEER 数据库的倾向评分匹配分析显示,卵巢鳞状细胞癌的预后较浆液性癌差。
J Ovarian Res. 2020 Jul 1;13(1):75. doi: 10.1186/s13048-020-00675-y.
5
Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.生物信息学分析确定了一种卵巢癌铂耐药相关风险特征。
Cancer Med. 2020 Feb;9(3):1242-1253. doi: 10.1002/cam4.2692. Epub 2019 Dec 19.
6
Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study.对接受卵巢癌手术的女性围手术期给予普萘洛尔:一项试点研究。
Obstet Gynecol Sci. 2017 Mar;60(2):170-177. doi: 10.5468/ogs.2017.60.2.170. Epub 2017 Mar 16.
7
The rise of genomic profiling in ovarian cancer.卵巢癌中基因组分析的兴起。
Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351. doi: 10.1080/14737159.2016.1259069.
8
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.晚期卵巢癌:初次减瘤手术还是中间减瘤手术?基于随机试验结果和肿瘤生物学特性的五类患者:晚期卵巢癌的初次减瘤手术和中间减瘤手术
Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23.
9
Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses.测定血清CRP、VEGF、瘦素、CK-MB、CA-15-3和IL-6水平以预测附件包块的恶性程度。
J Turk Ger Gynecol Assoc. 2011 Dec 1;12(4):214-9. doi: 10.5152/jtgga.2011.54. eCollection 2011.
10
A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer.以 CA-125 进行纵向分析预测卵巢癌患者的总生存期。
J Gynecol Oncol. 2014 Jan;25(1):51-7. doi: 10.3802/jgo.2014.25.1.51. Epub 2014 Jan 8.